Key points
- Initial EchoSolv HF 510(k) application not cleared for commercial use
- Company assessing options with FDA to seek clearance
- Strong financial position with over $105m in cash
- US uptake of EchoSolv AS continues to grow
- Broader R&D pipeline remains strong
Full summary
Echo IQ Limited (ASX: EIQ) has received a Not Substantially Equivalent (NSE) determination from the FDA for its initial EchoSolv HF 510(k) application. The company is reviewing the determination with its US regulatory and legal advisors and will engage with the FDA to clarify the issues and explore all available options. Echo IQ remains confident in the clinical rationale for EchoSolv HF and the significant unmet need in heart failure identification. The company will continue to progress its broader US commercial strategy and R&D pipeline, including the commercialization of EchoSolv AS and the development of new solutions.
Outlook
Echo IQ remains confident in the clinical rationale for EchoSolv HF and the significant opportunity to improve the identification of patients at risk of heart failure.